JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety ...
Tofacitinib 11mg, 22mg; ext-rel tabs. Swallow whole. 11mg once daily. Switching from immediate-rel to XR tabs: start XR tab the day following the last immediate-rel 5mg dose. Moderate to severe ...
Pfizer is already a player in the JAK inhibitor anti-inflammatory category with Xeljanz, but now has the first pivotal results for a drug that it hopes could sidestep safety issues with the class.